GlycoMimetics Reports Program Updates and Third Quarter 2017 Results
- Ongoing discussions with
U.S. Food and Drug Administration( FDA) regarding regulatory path for GMI-1271, including planned Phase 3 trial initiation in mid-2018
- Pro forma cash balance of
$132.1 millionas of September 30
- Two abstracts accepted as oral presentations at the 2017
American Society of Hematology(ASH) meeting in December
- Phase 3 clinical trial of rivipansel on track for completion in second half of 2018
The Company will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results today at
“In the third quarter of 2017, we initiated productive discussions with the
Key Operational Highlights for the Third Quarter of 2017:
GlycoMimeticsengaged with the FDAunder the terms of the Breakthrough Therapy designation the Company received in May. Discussions are focused on the design of a Phase 3 clinical trial protocol, including appropriate endpoints to capture GMI-1271’s potential benefits and a plan for other aspects of the program required for registration.
- Data related to GMI-1271 will be highlighted in two oral presentations at the 59th
American Society of Hematology(ASH) Annual Meeting and Expo. The ASH meeting will take place in Atlanta, GA, December 9-12, 2017. The oral presentations at the ASH meeting will include results from the ongoing Phase 1/2 clinical trial of GMI-1271, as well as a preclinical study in which the mechanism by which E-selectin mediates resistance to chemotherapy was observed. In the Phase 1/2 clinical trial, improved clinical outcomes were seen in both relapsed/refractory and newly diagnosed AML patients following treatment with GMI-1271. The preclinical data point to E-selectin dependent upregulation of tumor survival pathways, which are inhibited by GMI-1271.
- The rivipansel Phase 3 trial, being conducted by the Company’s collaborator Pfizer, is evaluating patients hospitalized for vaso-occlusive crisis of sickle cell disease. Pfizer reports that the study remains on track for completion in the second half of 2018.
Third Quarter 2017 Financial Results:
- Cash position: As of
September 30, 2017, GlycoMimeticshad cash and cash equivalents of $112.9 millionas compared to $40.0 millionas of December 31, 2016. The Company raised $86.8 millionin net proceeds from a public offering of common stock completed in May 2017. Subsequent to September 30, the Company raised an additional $19.2 millionin net proceeds under an at-the-market equity facility, resulting in a pro forma cash balance of $132.1 millionas of September 30.
- R&D Expenses: The Company’s research and development expenses decreased slightly to
$5.8 millionfor the quarter ended September 30, 2017as compared to $5.9 millionfor the third quarter of 2016. The decrease was primarily caused by lower clinical trial expenses related to the Phase 1/2 clinical trial of GMI-1271 for the treatment of AML due to patient enrollment completion in May 2017and a decrease in costs for non-clinical toxicology studies and clinical studies for GMI-1359. These decreases were offset in part by additional costs related to the manufacturing of Phase 3 clinical supplies of GMI-1271.
- G&A Expenses: The Company’s general and administrative expenses increased to
$2.4 millionfor the quarter ended September 30, 2017as compared to $2.0 millionfor the third quarter of 2016. These increases were primarily attributable to annual salary adjustments and stock-based compensation expense from 2017 equity awards to employees and directors.
- Shares Outstanding: Shares of common stock outstanding as of
September 30, 2017were 32,737,799.
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a Phase 1/2 clinical trial that has now completed enrollment, GMI-1271 is being evaluated in both newly diagnosed elderly and relapsed/refractory patients with acute myeloid leukemia (AML). In both populations in this trial, patients treated with GMI-1271 together with standard chemotherapy have achieved higher than expected remission rates based on historical controls, as well as lower than expected induction-related mortality rates. Importantly, treatment in these patient populations has been well tolerated with minimal adverse effects.
GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. Since E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow, the Company believes that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of both liquid and solid tumors that affect the bone marrow, as compared to targeting CXCR4 alone. GMI-1359 is currently being evaluated in a Phase 1 clinical trial.
Rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis (VOC) in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by GlycoMimetics’ strategic collaborator, Pfizer. Sickle cell disease is a genetic disease that, according to the
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the clinical development of the company’s drug candidates, including the expected timing of completion of clinical trials and the presentation of clinical data. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
|Condensed Statements of Operations|
|(In thousands, except share and per share data)|
Three months ended September 30,
|Nine months ended September 30,|
|Cost and expenses:|
|Research and development expense||5,780||5,921||17,380||17,221|
|General and administrative expense||2,402||1,984||7,016||6,352|
|Total costs and expenses||8,182||7,905||24,396||23,573|
|Loss from operations||(8,182||)||(7,887||)||(24,396||)||(23,555||)|
|Net loss and comprehensive loss||$||(7,950||)||$||(7,855||)||$||(24,023||)||$||(23,481||)|
|Net loss per share - basic and diluted||$||(0.24||)||$||(0.34||)||$||(0.86||)||$||(1.14||)|
|Weighted average shares - basic and diluted||32,724,010||23,049,347||27,814,781||20,638,129|
|Balance Sheet Data|
|September 30,||December 31,|
|Cash and cash equivalents||$||112,873||$||40,042|